Novartis cardiovascular-metabolic therapeutic teams are passionate about research, development and quality manufacturing of novel therapies and solutions to reduce the burden of diseases in communities around the world. We focus our efforts on diseases that negatively affect the heart, kidney, liver and blood vessels with the goal of better patient outcomes.
Novartis is dedicated to the research, development and manufacturing of ophthalmic pharmaceuticals and devices. The mission of Novartis in the field of ophthalmology is to discover, develop and manufacture innovative products to improve eye health and enhance people’s lives. Joint working in Ophthalmology
At Novartis, we are focused on improving the lives of the millions of people affected by respiratory and inflammation diseases and continue to research, develop and launch innovative therapies which treat chronic obstructive pulmonary disease, chronic spontaneous urticaria and severe allergic asthma.
The table below outlines our current research within respiratory and inflammation diseases:
Mechanism of action
Potential indication/ disease area
Route of administration
Planning filing dates
Anti-IgE monoclonal antibody
Chronic Spontaneous Urticaria
Indacaterol, mometasone furoate (in fixed-dose combination)
Long-acting beta2-agonist and inhaled corticosteroid
Indacaterol, mometasone furoate, glycopyrronium bromide (in fixed-dose combination)
Long-acting beta2 agonist, long-acting muscarinic antagonist and inhaled corticosteroid
Novartis has a strong 60-year history in neuroscience. We currently offer patients and physicians a large drug portfolio encompassing Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Epilepsy and Attention Deficit Hyperactivity Disorder (ADHD), and have a pipeline in Multiple Sclerosis, Alzheimer’s Disease and Neuromuscular therapies. In our research, we leverage advances in human genetics, new imaging technologies and other novel approaches to better understand brain disorders and continue bringing new drugs to patients worldwide.
Immunology and Dermatology
Our Immunology and Dermatology franchise aims to transform patients’ lives by targeting progressive illnesses and treating co-morbidities in the Specialty Dermatology, Rheumatology and Transplantation fields, where there are remaining high unmet medical needs.
Novartis Oncology is committed to the area of precision oncology treatment. Precision oncology is the evolving understanding of how cancers develop on a genomic level and our ability to develop drugs that hone in on those targets – ultimately leading to better patient outcomes. Our research, driven by a distinctive scientific and clinical strategy, focuses on unmet medical needs and disease pathways.
Cell and Gene Therapy
Novartis Pharmaceuticals has created a dedicated unit focused on the development and commercialisation of cell and gene therapies. The cell therapy portfolio aims to transform medical practice and help some patients suffering from a variety of life-threatening diseases including bloodborne cancers, sickle cell disease, thalassemias and other diseases of the blood by replacing, repopulating or resetting the immune system.
In the UK, it is estimated there are 3.5 million people who will be affected by a rare disease at some point in their lives. Despite the scale of the issue, a significant proportion of these patients do not have access to the right care and treatment.1
At Novartis, we are focused on improving the lives of the many people affected by several rare diseases, including tuberous sclerosis complex (TSC), acromegaly and Cushing’s disease. We seek to research, develop and provide a range of innovative medicines to help address unmet medical needs, as well as provide solutions to help improve the lives of patients living with these rare diseases. Click here for more information about our work in these areas.